133057-83-7

Basic information

• Product Name: 4-(Benzyloxy)-3-fluorophenylboronic acid
• Synonyms: AKOS BRN-0078;4-BENZYLOXY-3-FLUOROBENZENEBORONIC ACID;4-BENZYLOXY-3-FLUOROPHENYLBORONIC ACID;(3-FLUORO-4-BENZYLOXYPHENYL)BORONIC ACID;1-formylphenylboronic acid;4-Benzyloxy-3-fluorophenylboro;4-Benzyloxy-3-fluorobenzeneboronic acid 97%;4-Benzyloxy-3-fluorobenzeneboronicacid97%
• CAS NO: 133057-83-7
• Molecular Formula: C13H12BFO3
• Molecular Weight: 246.04
• EINECS: -0
• Product Categories: blocks;BoronicAcids;FluoroCompounds;Aryl;Fluorinated;Organoborons;Boronic acid;Boronate Ester;Potassium Trifluoroborate
• Mol File: 133057-83-7.mol

Chemical Properties

• Melting Point: 116 °C
• Boiling Point: 428°Cat760mmHg
• Flash Point: 212.6°C
• Appearance: /
• Density: 1.26g/cm³
• Vapor Pressure: 4.37E-08mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: soluble in Methanol
• PKA: 7.61±0.17(Predicted)
• CAS DataBase Reference: 4-(Benzyloxy)-3-fluorophenylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Benzyloxy)-3-fluorophenylboronic acid(133057-83-7)
• EPA Substance Registry System: 4-(Benzyloxy)-3-fluorophenylboronic acid(133057-83-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39-37/39-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 133057-83-7(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow crystal powde

Uses

suzuki reaction

InChI:InChI=1/C13H12BFO3/c15-12-8-11(14(16)17)6-7-13(12)18-9-10-4-2-1-3-5-10/h1-8,16-17H,9H2

Upstream product

• 121-43-7 Trimethyl borate 
• 7732-18-5 water 
• 133057-82-6 1-benzyloxy-4-bromo-2-fluorobenzene 
• 2105-94-4 4-bromo-2-fluorophenol 
• 100-39-0 benzyl bromide 

Downstream Products

• 1056266-01-3 1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-1H-indazol-4-ol 
• 1056263-55-8 1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-4-hydroxy-1H-indazole-6-carbonitrile 
• 1056263-40-1 1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-6-(methyloxy)-1H-indazol-4-ol 
• 1056263-69-4 6-fluoro-1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-1H-indazol-4-ol 
• 1056263-92-3 6-chloro-1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-1H-indazol-4-ol 
• 1056261-75-6 1-(3-fluoro-4-hydroxyphenyl)-4-hydroxy-1H-indazole-6-carbonitrile 
• 1056262-07-7 6-ethyl-1-(3-fluoro-4-hydroxyphenyl)-1H-indazol-4-ol 
• 1056261-99-4 6-ethenyl-1-(3-fluoro-4-hydroxyphenyl)-1H-indazol-4-ol 
• 1056261-91-6 6-bromo-1-(3-fluoro-4-hydroxyphenyl)-1H-indazol-4-ol 
• 1056261-67-6 1-(3-fluoro-4-hydroxyphenyl)-6-(methyloxy)-1H-indazol-4-ol 
• 1056261-83-6 6-fluoro-1-(3-fluoro-4-hydroxyphenyl)-1H-indazol-4-ol 
• 1056262-14-6 6-chloro-1-(3-fluoro-4-hydroxyphenyl)-1H-indazol-4-ol 
• 1056264-08-4 1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-6-methyl-1H-indazol-4-ol 
• 1056262-61-3 7-chloro-1-(3-fluoro-4-hydroxyphenyl)-1H-indazol-4-ol 

Relevant articles and documents

Polymerizable liquid crystal compound and preparation method and application thereof

The present invention relates to the field of liquid crystal display materials, and in particular relates to a novel polymerizable liquid crystal compound as well as a preparation method and application thereof. The general structure of the liquid crystal compound is shown in the description, wherein R represents alkyl with 1-10 carbon atoms or alkoxy with 1-10 carbon atoms, a ring A represents 1,4-phenylene of which 1-4 hydrogen atoms are replaced by fluorine atoms, and m is 1 or 2. The present invention also provides a liquid crystal composition comprising 0.05%-20% by weight of the above compound, and the liquid crystal composition containing the compound provided by the present invention has physical properties such as a high upper limit temperature of a nematic phase and a low minimumlimit temperature of the nematic phase, small viscosity, appropriate optical anisotropy, large dielectric anisotropy, an appropriate elastic constant and an appropriate pretilt angle, and wide application prospects.

CYCLOALKYLAMINE DERIVATIVE

Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure